首页> 外文OA文献 >Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding
【2h】

Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding

机译:配体与低密度脂蛋白受体相关蛋白的第二类补体重复序列结合的分子分析。受体相关蛋白介导的配体结合抑制中的变构成分的证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The low density lipoprotein receptor-related protein (LRP), a member of the low density lipoprotein receptor gene family, mediates the cellular uptake of a diversity of ligands. A folding chaperone, the 39-kDa receptor-associated protein (RAP) that resides in the early compartments of the secretory pathway inhibits the binding of all ligands to the receptor and may serve to prevent premature binding of ligands to the receptor during the trafficking to the cell surface. To elucidate the molecular interactions that underlie the interplay between the receptor, RAP, and the ligands, we have analyzed and delineated the binding sites of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA).PAI-1 complexes, RAP, and the anti-LRP Fab fragment Fab A8. To that end, we have generated a series of soluble recombinant fragments spanning the second cluster of complement-type repeats (C3-C10) and the amino-terminal flanking epidermal growth factor repeat (E4) of LRP (E4-C10; amino acids 787-1165). All fragments were expressed by stably transfected baby hamster kidney cells and purified by affinity chromatography. A detailed study of ligand binding to the fragments using surface plasmon resonance revealed the presence of three distinct, Ca2+-dependent ligand binding sites in the cluster II domain (Cl-II) of LRP. t-PA.PAI-1 complexes as well as PAI-1 bind to a domain located in the amino-terminal portion of Cl-II, spanning repeats E4-C3-C7. Adjacent to this site and partially overlapping is a high affinity RAP-binding site located on repeats C5-C7. Fab A8, a pseudo-ligand of the receptor, binds to a third Ca2+-dependent binding site on repeats C8-C10 at the carboxyl-terminal end of Cl-II. Next, we studied the RAP-mediated inhibition of ligand binding to LRP and to Cl-II. As expected, we observed a strong inhibition of t-PA.PAI-1 complex and Fab A8 binding to LRP by RAP (IC50 congruent with 0.3 nM), whereas in the reverse experiment, competition of t-PA. PAI-1 complexes and Fab A8 for RAP binding to LRP could only be shown at high concentrations of competitors (>/=1 microM). Interestingly, even though the equilibrium dissociation constants for the binding of RAP to LRP and to Cl-II are similar, the binding of the ligands to Cl-II is only prevented by RAP at concentrations that are at least 2 orders of magnitude higher than those required for inhibition of ligand binding to LRP. Our results favor models that propose RAP-induced allosteric inhibition of ligand binding to LRP that may require LRP moieties that are located outside Cl-II of the receptor
机译:低密度脂蛋白受体相关蛋白(LRP)是低密度脂蛋白受体基因家族的成员,介导细胞对多种配体的摄取。折叠伴侣,一种39 kDa受体相关蛋白(RAP),位于分泌途径的早期区室,可抑制所有配​​体与受体的结合,并可能在运输过程中阻止配体与受体的过早结合。细胞表面。为了阐明构成受体,RAP和配体之间相互作用的基础的分子相互作用,我们分析并描绘了纤溶酶原激活物抑制剂-1(PAI-1),组织型纤溶酶原激活物(t-PA)的结合位点。 PAI-1复合物,RAP和抗LRP Fab片段Fab A8。为此,我们产生了一系列可溶性重组片段,这些片段跨越第二类补体型重复序列(C3-C10)和LRP(E4-C10;氨基酸787氨基酸)的氨基末端侧翼表皮生长因子重复序列(E4) -1165)。所有片段均通过稳定转染的幼仓鼠肾细胞表达,并通过亲和层析纯化。使用表面等离子体共振对配体与片段结合的详细研究表明,LRP的簇II结构域(Cl-II)中存在三个不同的,依赖Ca2 +的配体结合位点。 t-PA.PAI-1复合物以及PAI-1结合到位于Cl-II氨基末​​端部分的结构域,跨越重复E4-C3-C7。与该位点相邻且部分重叠的是位于重复序列C5-C7上的高亲和力RAP结合位点。 Fab A8是受体的伪配体,在C1-II的羧基末端与重复C8-C10上的第三个Ca2 +依赖性结合位点结合。接下来,我们研究了RAP介导的配体与LRP和Cl-II结合的抑制作用。如预期的那样,我们观察到RAP对t-PA.PAI-1复合物和Fab A8与LRP的结合具有强烈的抑制作用(IC50与0.3 nM一致),而在相反的实验中,t-PA则竞争。 RAI与LRP结合的PAI-1复合物和Fab A8仅在高浓度竞争者(> / = 1 microM)下显示。有趣的是,即使RAP与LRP和Cl-II结合的平衡解离常数相似,配体与Cl-II的结合也只能通过RAP阻止,其浓度至少比其高2个数量级。抑制配体与LRP结合所需。我们的结果支持提出RAP诱导的配体与LRP结合的变构抑制的模型,这可能需要位于受体Cl-II外部的LRP部分

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号